# A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

> **NCT06568458** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 71 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** BMS 986278

## Key facts

- **NCT ID:** NCT06568458
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-19
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-02-27
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06568458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06568458, "A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06568458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*